Cannabics Pharmaceuticals Valuation
| CNBX Stock | USD 0.01 0.00 0.00% |
Cannabics Pharmaceuticals seems to be overvalued based on Macroaxis valuation methodology. Our model approximates the value of Cannabics Pharmaceuticals from analyzing the firm fundamentals such as Shares Owned By Insiders of 57.59 %, current valuation of 6.67 M, and Return On Equity of -42.89 as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Cannabics Pharmaceuticals' price fluctuation is out of control at this time. Calculation of the real value of Cannabics Pharmaceuticals is based on 3 months time horizon. Increasing Cannabics Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Cannabics Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Cannabics Pink Sheet. However, Cannabics Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.01 | Real 0.007434 | Hype 0.01 | Naive 0.0102 |
The intrinsic value of Cannabics Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Cannabics Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Cannabics Pharmaceuticals helps investors to forecast how Cannabics pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Cannabics Pharmaceuticals more accurately as focusing exclusively on Cannabics Pharmaceuticals' fundamentals will not take into account other important factors: Cannabics Pharmaceuticals Total Value Analysis
Cannabics Pharmaceuticals is currently forecasted to have valuation of 6.67 M with market capitalization of 123.28 K, debt of 1.6 M, and cash on hands of 96.28 K. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Cannabics Pharmaceuticals fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
6.67 M | 123.28 K | 1.6 M | 96.28 K |
Cannabics Pharmaceuticals Asset Utilization
One of the ways to look at asset utilization of Cannabics is to check how much profit was generated for every dollar of assets it reports. Cannabics Pharmaceuticals shows a negative utilization of assets of -1.0 percent, losing $0.01 for each dollar of assets held by the firm. Inadequate asset utilization signifies that the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Cannabics Pharmaceuticals shows how discouraging it operates for each dollar spent on its assets.Cannabics Pharmaceuticals Ownership Allocation
Cannabics Pharmaceuticals retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares.Cannabics Pharmaceuticals Profitability Analysis
Net Loss for the year was (3.72 M) with profit before overhead, payroll, taxes, and interest of 7.16 K.About Cannabics Pharmaceuticals Valuation
Our relative valuation model uses a comparative analysis of Cannabics Pharmaceuticals. We calculate exposure to Cannabics Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Cannabics Pharmaceuticals's related companies.CNBX Pharmaceuticals Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of cannabinoid-based treatments and therapies for cancer. CNBX Pharmaceuticals Inc. was incorporated in 2004 and is based in Bethesda, Maryland. Cnbx Pharmaceuticals operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 10 people.
8 Steps to conduct Cannabics Pharmaceuticals' Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Cannabics Pharmaceuticals' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Cannabics Pharmaceuticals' valuation analysis, follow these 8 steps:- Gather financial information: Obtain Cannabics Pharmaceuticals' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Cannabics Pharmaceuticals' revenue streams: Identify Cannabics Pharmaceuticals' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Cannabics Pharmaceuticals' industry and market trends, including the size of the market, growth rate, and competition.
- Establish Cannabics Pharmaceuticals' growth potential: Evaluate Cannabics Pharmaceuticals' management, business model, and growth potential.
- Determine Cannabics Pharmaceuticals' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Cannabics Pharmaceuticals' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Cannabics Pharmaceuticals Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 1.3 M | |
| Retained Earnings | -20.5 M |
Additional Tools for Cannabics Pink Sheet Analysis
When running Cannabics Pharmaceuticals' price analysis, check to measure Cannabics Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cannabics Pharmaceuticals is operating at the current time. Most of Cannabics Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Cannabics Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cannabics Pharmaceuticals' price. Additionally, you may evaluate how the addition of Cannabics Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.